2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro- 6-methyl-3,5-pyridinedicarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro- 6-methyl-3,5-pyridinedicarboxylic acid
• 英文别名: 2-(2-Aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid
• 化学式: C₁₇H₁₉ClN₂O₅
• 分子量: 366.801
• InChiKey: QQUGAJMOSWOMFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  苯磺酸氨氯地平 在 盐酸 、 水 作用下， 反应 2.0h， 生成 2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro- 6-methyl-3,5-pyridinedicarboxylic acid
  参考文献：
  名称：

  Advanced stability indicating chemometric methods for quantitation of amlodipine and atorvastatin in their quinary mixture with acidic degradation products

  摘要：

  Two advanced, accurate and precise chemometric methods are developed for the simultaneous determination of amlodipine besylate (AML) and atorvastatin calcium (ATV) in the presence of their acidic degradation products in tablet dosage forms. The first method was Partial Least Squares (PLS-1) and the second was Artificial Neural Networks (ANN). PLS was compared to ANN models with and without variable selection procedure (genetic algorithm (GA)). For proper analysis, a 5-factor 5-level experimental design was established resulting in 25 mixtures containing different ratios of the interfering species. Fifteen mixtures were used as calibration set and the other ten mixtures were used as validation set to validate the prediction ability of the suggested models. The proposed methods were successfully applied to the analysis of pharmaceutical tablets containing AML and ATV. The methods indicated the ability of the mentioned models to solve the highly overlapped spectra of the quinary mixture, yet using inexpensive and easy to handle instruments like the UV-VIS spectrophotometer. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2015.10.007

文献信息

• Active agent delivery systems and methods for protecting and administering active agents
  申请人：New River Pharmaceuticals Inc.

  公开号：US20040063628A1

  公开（公告）日：2004-04-01

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽的组成部分，与活性物质共价连接的组合物和用于给予共轭活性物质组合物的方法。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090253792A1

  公开（公告）日：2009-10-08

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸（作为单个氨基酸或肽）与活性剂共价连接的组合物以及给予共轭活性剂组合物的方法。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090306228A1

  公开（公告）日：2009-12-10

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽，与活性剂共价结合的组合物以及用于给予共轭活性剂组合物的方法。
• METHOD OF TREATING A PATHOLOGICAL SYNDROME
  申请人：Epshtein Oleg Iliich

  公开号：US20160229914A1

  公开（公告）日：2016-08-11

  A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.

  一种治疗与神经递质的细胞内信号传递相关的疾病或症状的方法，包括给予一种高度稀释的抗原抗体制剂，该抗原是一种能够影响神经受体的细胞内信号传递的分子，特别是多巴胺或血清素。
• Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
  申请人：SEPRACOR, INC.

  公开号：EP1013275A2

  公开（公告）日：2000-06-28

  Methods and compositions are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liabiliy of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (-) amlodopine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodopine.

  本研究公开了利用氨氯地平光学纯（-）异构体的方法和组合物。这种化合物是治疗高血压的强效药物，同时避免了与氨氯地平外消旋混合物相关的不良反应。氨氯地平的(-)异构体还可用于治疗心绞痛和其他可能与(-)氨氯地平作为钙通道拮抗剂的活性有关的病症，如脑缺血、脑功能紊乱、心律失常、心脏肥大、冠状动脉血管痉挛、心肌梗塞、肾功能损害和急性肾衰竭，而不会同时产生与氨氯地平外消旋混合物有关的不良反应。